Bayer CropScience on the announcement by the EU Commission: Commission’s plan will not have a positive impact on bee health
Melbourne, 30 April 2013 – Bayer CropScience considers the decision by the Commission of the European Union to restrict the use of neonicotinoid-containing products across Europe as a set-back for technology, innovation and sustainability. In an Appeals Committee meeting today, only half of the EU Member States supported the Commission's proposal for the restrictions. The company believes that the plan by the Commission will not have a positive impact on bee health.
The company is concerned that the restriction of these neonicotinoids will result in crop yield losses, reduced food quality and loss of competitiveness for European agriculture. This will have a negative impact on farmers, R&D driven ag companies, the seed industry and the food value chain.
As a science-based company, Bayer CropScience is disappointed that clear scientific evidence has taken a back-seat in the decision making process. This disproportionate decision is a missed opportunity to reach a solution that takes into consideration all of the existing product stewardship measures and broad stakeholder concerns. The further reduction of effective crop protection products will put at risk farmers' ability to tackle the important pests that can severely restrict their ability to grow high-quality food.
Bayer CropScience remains convinced that neonicotinoids are safe for bees, when used responsibly and properly, according to label instructions. The company will work together with all relevant stakeholders and authorities in the Member States to handle the complex consequences of this decision, to further support its customers.
More information on the Bayer Bee Care program can be found at www.beecare.bayer.com.
In Australia the Australian Pesticides and Veterinary Medicines Authority (APVMA) is also reviewing the safety of neonicitinoid products to honey bees and other pollinators, utilising all available scientific data. Until this review is complete, it is unclear whether any further regulation will be required.
Australia is recognised as having the healthiest population of honey bees in the world. This has been widely associated with the absence of the deadly varroa mite in Australia.
Bayer CropScience’s firm view is that neonicotinoids are not harmful to bees, when used in accordance with label instructions.
Bayer will continue to work with the Australian regulatory authorities, industry bodies and beekeepers to ensure that the use of these important insecticides does not in any way cause harm to the Australian honeybee population.
This includes sharing research from around the world and the latest information coming out of Bayer’s bee health centres.
More information can be found at www.beecare.bayer.com.
Fleur Wilkins (03) 9248 6851
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. This year the company is celebrating 150 years of Bayer – consistent with its mission “Bayer: Science For A Better Life”. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 8,383 million (2012) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 20,800 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.